- First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial -ATLANTA, Aug. 03, 2023 (GLOBE…
MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and…
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the…
Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board of DirectorsTHE WOODLANDS, Texas, July…
VANCOUVER, BC / ACCESSWIRE / July 25, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is excited to…
Latest fundraising effort to strengthen Emagine’s powerful suite of maternal health toolsTUCSON, Ariz.--(BUSINESS WIRE)--Emagine Solutions Technology has been awarded $1…
Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of…
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary…
Emergent has been delivering CYFENDUS™ vaccine to the U.S. Department of Health and Human Services since 2019, under pre-Emergency Use…